In patients with impaired renal function, careful adjustment of gentamicin dosage is required to achieve therapeutic yet nontoxic concentrations. Two regimens that differ in pharmacodynamic characteristics have been recom- The high degree of variability in peak serum levels of gentamicin (8, 11, 12) and the narrow margin between optimal therapeutic and potentially toxic doses (1, 6) have resulted in recommendations by many investigators to determine serum gentamicin levels frequently during therapy to ensure optimal treatment of infections and to avoid drug toxicity. In patients with impaired renal function, two methods which differ markedly in pharmacodynamic characteristics have been recommended for adjusting the dosage of gentamicin to compensate for the reduced renal clearance: (i) administering a loading dose and then prolonging the intervals between administration of similar maintenance doses of gentamicin (variable frequency regimen [VFR]) (3, 4, 9), or (ii) giving a loading dose of gentamicin followed at the usual time intervals, generally every 8 h, by reduced maintenance doses (variable dosage regimen [VDR]) (2). Dosages with both regimens are calculated to produce similar peak serum levels of genta-' Present address: Presbyterian Hospital of Dallas, Dallas, Tex. 75231. micin. With the VDR, the trough serum levels of gentamicin are determined by the severity of renal insufficiency and should be 50% or more of the preceding peak levels when the half-life of gentamicin in serum exceeds the interval between doses. Thus, in patients with severe renal insufficiency treated by the VDR, serum gentamicin levels during therapy should continuously approximate or exceed the minimal inhibitory concentration of gentamicin for many aerobic gram-negative bacilli. In contrast, the intervals between doses with the VFR are calculated to allow the concentration of gentamicin in serum to decline to trough levels that are 25% or less of peak levels. Thus, gentamicin serum levels in patients with severe renal failure on the VFR might be suboptimal for periods of many hours. Few clinical data are available concerning possible differences either in the therapeutic efficacy or in the risk of oto-or nephrotoxicity between VDR and VFR for administration of gentamicin to patients with renal insufficiency
In patients with impaired renal function, careful adjustment of gentamicin dosage is required to achieve therapeutic yet nontoxic concentrations. Two regimens that differ in pharmacodynamic characteristics have been recommended for this purpose: prolonging the intervals between administration of equal doses (variable frequency regimen [VFR] ) or administering a loading dose followed at the usual intervals by reduced maintenance doses (variable dosage regimen [VDR] ). These regimens were compared in a prospective, randomized study of 20 seriously ill hospitalized patients, 10 on VFR and 10 on VDR. Wide variability in peak serum levels of gentamicin was observed both between patients and in individual patients after separate injections of the same dosage. As predicted by the design of these regimens, the trough serum levels of gentamicin correlated significantly with the serum creatinine concentrations in patients on the VDR but not in patients on the VFR. A gentamicin trough level of >4 ,ug/ml was the only variable among those tested that correlated significantly with development or progression of renal insufficiency during treatment with gentamicin, but such trough levels were observed frequently on both regimens. Whereas this study does not permit a direct comparison of the therapeutic efficacy of VDR and VFR, no difference in the risk of nephrotoxicity with these regimens was observed.
The high degree of variability in peak serum levels of gentamicin (8, 11, 12) and the narrow margin between optimal therapeutic and potentially toxic doses (1, 6) have resulted in recommendations by many investigators to determine serum gentamicin levels frequently during therapy to ensure optimal treatment of infections and to avoid drug toxicity. In patients with impaired renal function, two methods which differ markedly in pharmacodynamic characteristics have been recommended for adjusting the dosage of gentamicin to compensate for the reduced renal clearance: (i) administering a loading dose and then prolonging the intervals between administration of similar maintenance doses of gentamicin (variable frequency regimen [VFR]) (3, 4, 9) , or (ii) giving a loading dose of gentamicin followed at the usual time intervals, generally every 8 h, by reduced maintenance doses (variable dosage regimen [VDR]) (2) . Dosages with both regimens are calculated to produce similar peak serum levels of genta-micin. With the VDR, the trough serum levels of gentamicin are determined by the severity of renal insufficiency and should be 50% or more of the preceding peak levels when the half-life of gentamicin in serum exceeds the interval between doses. Thus, in patients with severe renal insufficiency treated by the VDR, serum gentamicin levels during therapy should continuously approximate or exceed the minimal inhibitory concentration of gentamicin for many aerobic gram-negative bacilli. In contrast, the intervals between doses with the VFR are calculated to allow the concentration of gentamicin in serum to decline to trough levels that are 25% or less of peak levels. Thus, gentamicin serum levels in patients with severe renal failure on the VFR might be suboptimal for periods of many hours. Few clinical data are available concerning possible differences either in the therapeutic efficacy or in the risk of oto-or nephrotoxicity between VDR and VFR for administration of gentamicin to patients with renal insufficiency (2) (3) (4) 9 
MATERIALS AND METHODS
Subjects included in the study were seriously ill patients on the medical service at Parkland Memorial Hospital, Dallas, Tex., who were being treated with intramuscular gentamicin by their primary physicians either for documented specific infections or for empirical initial therapy of suspected gram-negative bacillary sepsis. VDR and VFR were randomized; patients with even hospital unit numbers were treated by the VFR, and those with odd hospital unit numbers were treated by the VDR. Patients were examined daily by one of us, and therapy with gentamicin was discontinued as soon as permitted by clinical indications.
In the VFR that has been standard at this hospital, an initial dose of 1.5 mg of gentamicin per kg was administered and subsequent doses of 1.5 mg/kg were administered at a frequency in hours equal to eight times the concentration of serum creatinine in mg/100 ml. The intervals were rounded off to the nearest even number of hours. For example, a patient weighing 50 kg with a serum creatinine of 2.9 mg/100 ml received 75 mg of gentamicin every 24 h.
In the VDR a loading dose of 1.7 mg of gentamicin per kg was given, and subsequent doses were administered every 8 (7) were used to determine the first maintenance dose.
Specimens for determinations of peak serum levels were collected 1 h after intramuscular injection of gentamicin, and those for trough levels were collected 30 min or less before a dose. Peak and trough serum gentamicin levels and serum creatinine concentrations were performed once daily, and timed 4-h creatinine clearances were measured three times each week if possible. Serum specimens were stored at -20 C until assays for gentamicin were performed by an enzymatic method described previously (5) . Concentrations of creatinine in serum and urine were performed in the clinical laboratory at Parkland Memorial Hospital by standard automated methods. Linear regression analysis was performed by the least squares method, and other statistical analyses were performed by the two-tailed Student's t test or by the chi-square test.
RESULTS AND DISCUSSION Twenty patients were studied, ten treated by the VFR and ten by the VDR. There were no statistically significant differences between the two treatment groups as to age, sex, racial distribution, duration of gentamicin therapy, cumulative dosage of gentamicin, or serum creatinine concentration or creatinine clearance at the start of treatment (P > 0.10 for each characteristic). The mean initial serum creatinine concentration was 1.6 + 1.2 mg/100 ml for patients treated by the VFR and 2.5 ± 1.5 mg/100 ml for patients treated by the VDR. Six of ten patients in the VFR and seven of ten in the VDR had impaired renal function with serum creatinine concentrations exceeding 1.0 mg/100 ml and with creatinine clearances less than 70 ml/min per 1.73 m2 at the start of therapy with gentamicin.
An estimate of the pharmacokinetic response resulting from individual doses of gentamicin that is essentially independent of renal function can be obtained by calculating the difference, AG, between the peak serum level of gentamicin achieved after a dose and the trough level immediately preceding that dose. The doseresponse curve presented in Fig. 1 was constructed by plotting 47 measurements of AG against the corresponding dosages of gentamicin. From this dose-response curve, the predicted average increment in serum gentamicin concentration after an intramuscular dose of 1.5 mg/kg is 3.9 ,ug/ml. At any given dosage of gentamicin the observed values of AG varied widely, and this variability is reflected by the low value (0.60) for the linear correlation coefficient (Fig. 1) . Three or more measurements of AG were performed with serum specimens collected at different times from each of seven patients, and wide variations in the values of AG at any given dosage of gentamicin were observed both in individual patients at different times and in different patients.
As predicted by the design of the VDR, trough gentamicin levels were highest in patients with the most severe renal insufficiency ( Fig. 2A) levels were also observed in patients treated by the VFR (Fig. 2B) , there was no significant correlation between gentamicin trough levels and serum creatinine concentrations on this regimen (r = 0.28, P > 0.10). In fact, most of the trough levels exceeding 2 ,ug/ml with the VFR occurred in four patients whose initial serum creatinine concentrations of 1.1, 1.2, 1.4 and 2.0 mg/100 ml did not adequately reflect their low creatinine clearances of 59, 32, 29, and 17 ml/min per 1.73 M2. Under these circumstances, accumulation of gentamicin occurred during therapy because the calculated dosage interval based on serum creatinine concentration was too short in comparison with the severity of renal insufficiency.
The development or progression of renal insufficiency as indicated by an increase in serum creatinine concentration to a value at least 1.0 mg/100 ml above the value at the start of gentamicin therapy was common and occurred in five of ten patients treated by the VDR and in two of six patients treated by the VFR (Table  1) . Four additional patients treated by the VFR were excluded from analysis because the duration of gentamicin therapy was 2 days or less and repeated measurements of gentamicin and creatinine concentrations were not performed.
Patients in whom a rise in serum creatinine concentration of 1.0 mg/100 ml or greater occurred and those in whom it did not occur (Table 1) ,ug/ml at any time during therapy (P > 0.10 for each variable). In contrast, a statistically significant correlation was observed between a trough gentamicin level > 4 gg/ml on one or more occasions during treatment and an increase in serum creatinine concentration of > 1.0 mg/100 ml (chi square = 4.89, P = 0.027). An elevated trough level of this magnitude was observed in all seven patients with a rising serum creatinine concentration but in only three of nine patients without such a rise in creatinine concentration during treatment by both regimens (Table 1) . Although the averages of the initial creatinine clearances were quite different for patients on the VDR with and without a rising serum creatinine concentration during therapy with gentamicin (Table 1) , this difference was not statistically significant (0.05 < P < 0.1). Thus, a gentamicin trough level of >4 ,ug/ml was the only variable among those tested that correlated significantly with development or progression of renal insufficiency.
Our observations support the previous suggestion (J. Dahlgren and W. Hewitt, Prog. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., 13th, Washington, D.C., Abstr. 57, 1973) that elevated trough levels of gentamicin are statistically associated with nephrotoxicity, but they do not provide evidence for a cause and effect relationship. Although differences in nephrotoxicity between the VDR and VFR were not observed in the present study, such a correlation could have been obscured by the unexpectedly high incidence of elevated gentamicin trough levels in our small population of patients treated by the VFR. Because the severity of renal insufficiency cannot be accurately determined by measurements of serum creatinine concentration in many seriously ill or elderly patients, we recommend that modifications in the dosage of gentamicin be based on creatinine clearances or other appropriate assessments of the glomerular filtration rate in patients treated by the VFR as well as in patients treated by the VDR. This precaution should reduce the incidence of elevated trough levels of gentamicin in patients treated by the VFR and should make it possible to compare the potential toxicity of the VDR and VFR with greater precision in future prospective studies. (10) (11) (12) , and retrospective studies suggest that less than 2 days in whom repeated gentamicin ototoxicity is correlated with peak serum levels exceeding 10 /sg/ml (6 sive accumulation of gentamicin during therapy and indicate that the dosage of gentamicin should be reduced. These observations on gentamicin may also be applicable to the newer and closely related deoxystreptamine containing aminoglycoside antibiotics, tobramycin and sisomicin.
